๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C

โœ Scribed by M. S. Seyam; D. A. Freshwater; K. O'Donnell; D. J. Mutimer

Book ID
108885800
Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
84 KB
Volume
12
Category
Article
ISSN
1352-0504

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Merimepodib, pegylated interferon, and r
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders
โœ Vinod K. Rustgi; William M. Lee; Eric Lawitz; Stuart C. Gordon; Nezam Afdhal; Fr ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 240 KB ๐Ÿ‘ 1 views

on behalf of the MErimepodib TRiple cOmbination (METRO) study group Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC) when combined with pegylated interferon alfa 2a (Peg-IFN-a